QDEL QUIDEL CORP

QuidelOrtho Announces the Formation of the International QuidelOrtho Women’s Leadership Network (QWLN)

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, celebrates Women’s History Month by announcing that the QuidelOrtho Women’s Leadership Network (QWLN) has been formed, creating an enhanced network with 14 global leaders supporting 16 chapters around the world.

In 2022, Quidel Corporation and Ortho Clinical Diagnostics united as QuidelOrtho. Leaders from both companies’ women’s leadership networks came together to form QWLN, a global women-led organization amplifying the mentoring, empowerment, achievement and visibility of women. Because Women’s History Month was created to highlight the achievements women have made throughout history, it is the perfect time to share information about this expanding network. QWLN encourages and inspires members to stretch beyond their primary functions and learn about other areas of interest by serving on various committees.

“It is with great pleasure that we announce the launch of the QuidelOrtho Women’s Leadership Network, a global community built around the spirit of both professional and personal development and sharing insights on modern issues our leaders face every day,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho. “At QuidelOrtho, we aspire to lead by example in becoming a truly transformational global diagnostics company with a vibrant workplace.”

Setting the stage for many more company opportunities, the QWLN brings educational content, recognition, research and thought leadership in support of professional women at all levels of the organization. Today, QWLN has successfully launched 16 worldwide chapters representing employees from various regions within North America, Latin America, Asia Pacific, Europe, the Middle East and Africa.

QWLN programming is designed to bring members together to exchange ideas and education through speaking engagements, training programs, book clubs, topic-specific events, luncheons, community activities and so much more.

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.

Ranked among the world’s largest in vitro diagnostics (IVD) providers with more than 120 years of collective experience, we combine industry-leading expertise in immunoassay and molecular testing with a global footprint in clinical labs and transfusion medicine.

Our company’s comprehensive product portfolio delivers accuracy, speed, automation and access, providing critical information when and where it is needed most. Inspired by a spirit of service, QuidelOrtho is committed to enhancing the well-being of people worldwide and happy in the knowledge we are making a difference. For more information, please visit .

Source: QuidelOrtho Corporation

EN
28/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QUIDEL CORP

 PRESS RELEASE

QuidelOrtho® Introduces Results Manager™ System

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address the growing demands of modern laboratories. The Results Manager system provides a seamless, user-friendly experience for community hospitals and point-of-care settings, strengthening informatics capabilities across QuidelOrtho's extensive diagnostics portfolio. This press release features multimedia. View the full release here: QuidelOrtho® Results Manager™ System (Graphic: Business Wire) The Quid...

 PRESS RELEASE

QuidelOrtho to Participate in the 46th Annual Raymond James Institutio...

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 46th Annual Raymond James Institutional Investor Conference on Wednesday, March 5, 2025. Members of QuidelOrtho’s management team will participate in a presentation at 8:40 a.m. ET / 5:40 a.m. PT. Interested parties can access the live webcast and replay in the “Events & Presentations” section ...

 PRESS RELEASE

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Result...

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 29, 2024. “We are pleased with our 2024 business performance and ended the year with positive momentum leading into 2025,” said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. “The growth of our underlying business with its recurring revenue busin...

 PRESS RELEASE

QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter...

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue for the fourth quarter ended December 29, 2024. Fourth Quarter 2024 Preliminary Unaudited Revenues The Company expects total reported revenues for the fourth quarter of 2024 to be in the range of approximately $702 million to $707 million, which would be in line with its previously announced 2024 financia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch